Through its GV venture capital arm (formerly Google Ventures prior to the restructuring of Google), Alphabet is taking an equity stake in companies looking to reduce human suffering and increase human life expectancy. These are firms aiming to limit aging and improve how we treat diseases by researching areas like genomics, cell therapy, and biotechnology.